Slide 1: Three Platforms, One Mission
THREE PLATFORMS, ONE MISSION TRANSFORMING ADVANCED CANCER CARE NASDAQ: RNAZ
Slide 2: Company Forward Looking Statement
COMPANY FORWARD LOOKING STATEMENT Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the “Company”), you should read TransCode’s filings with the U.S. Securities and Exchange Commission (“SEC”) for more complete information about the Company. You can obtain these doc
Slide 3: A Rare Small-Cap with Three Near Term Catalysts
A RARE SMALL-CAP RNA-targeted therapeutics that WITH THREE NEAR precisely reach tumors: prioritized TERM CATALYSTS Harvard-faculty founders Massachusetts General Hospital (MGH) /Harvard Medical School (HMS) to Vaccine immunotherapies that target advanced cancers mobilize the immune system to recogni
Slide 4: Critical Need for Effective Therapies Targeting Advanced Cancer
CRITICAL NEED FOR EFFECTIVE THERAPIES TARGETING ADVANCED CANCER CANCER DEATHS DUE TO LOW SURVIVAL IF DIAGNOSED AT ADVANCED STAGE ADVANCED DISEASE 5-year Relative Survival: Advanced vs Not Advanced Cancer (SEER- >90% derived) Prostate 100% 32 % ADVANCED CANCER Reduces 5-year Survival Female Breast 92
Slide 5: Experienced Management
EXPERIENCED MANAGEMENT PHILIPPE P. CALAIS ZDRAVKA MEDAROVA, JOHN TATTORY LOU BRENNER, MD PharmD, PhD PhD Interim CFO Consulting Clinical and CEO, Chairman of the Board Co-founder, CSO Strategic Advisor TANIA MONTGOMERY, DANIEL VLOCK, MD MICHEL JANICOT, PhD MBA Consulting Oncology Consulting Head VP
Slide 6: Leading Advisors with Oncology and RNA Expertise
LEADING ADVISORS WITH ONCOLOGY AND RNA EXPERTISE BOARD OF DIRECTORS PHILIPPE P. CALAIS, PharmD PhD MAGDA MARQUET, PhD ELIZABETH CZEREPAK, MBA Chairman and CEO Co-CEO, ALMA Life Science CFO, Mirror Biologics JACK E. STOVER ERIK MANTING, PhD Chairman, Traws Pharma CEO, Mendus AB SCIENTIFIC ADVISORY BO
Slide 7: Innovative and Differentiated Pipeline
INNOVATIVE AND DIFFERENTIATED PIPELINE Indication Preclinical IND Enabling Phase 0 Phase 1 Phase 2 Phase 3 ASO mCRC TTX-MC138 Cancer Stage 2B & 2C SEVIPROTIMUT-L vaccine Melanoma Combi- Undisclosed TTX-MC138 SEVIPROTIMUT-L nation RNAi Pancreatic TTX-siPD-L1 Ai R N Cancer PRR Cancer Agnostic TTX-RIGA
Slide 8: TTX-MC138
TTX-MC138 LEAD THERAPEUTIC CANDIDATE ANTAGOMIR TARGETING MiRNA-10b PHASE 2a ACTIVE 8
Slide 9: TTX-MC138
TTX-MC138 Select miR-10b Molecular Pathways TWIST Iron oxide nanoparticle platform designed for 1 the delivery of RNA therapeutics to tumors miR-10b TTX- MC138 Nucleic acid-based therapeutic designed to bind HOXD1O NF1 TBX5 Type to a specific microRNA and block its function E-Cadherin RHOC ROCK PTE
Slide 10: Clinical Development Plan: Metastatic Disease
CLINICAL DEVELOPMENT PLAN: METASTATIC DISEASE Phase 0 Phase 1a Phase 2a Phase 2 Microdose radio labelled, Dose escalation, all comers, Dose expansion First indication TBD advanced solid tumors advanced solid tumors Micrometastatic disease 2023 2024 2025 2026 2027 2028 Phase 0 Phase 1a Phase 2a Phase
Slide 11: Phase 0: Accumulation in Metastatic Lesions Confirmed
PHASE 0: ACCUMULATION IN METASTATIC LESIONS CONFIRMED PRE-DOSING POST-DOSING Dosed 1 female patient with stage-IV metastatic breast cancer (metastatic sites: bone, liver and lungs – left panel) Single sub-therapeutic dose of labelled TTX-MC138 PET-MRI performed at 2, 3, 6 and 24 hours post-dosing (r
Slide 12: Phase 1a Trial: Overview and Status
PHASE 1a TRIAL: OVERVIEW AND STATUS Dose escalation, 4 cohorts of 3 + patients Advanced solid tumors, all comers OBJECTIVES ENDPOINTS PHASE 1A HIGHLIGHTS* Primary Objectives Primary Endpoint # Subjects Treated 16 ACHIEVED # Doses to Date ~ 98 Evaluate safety and tolerability, determine MTD Incidence
Slide 13: Phase 1a Trial: Subject Tumor Type
PHASE 1a TRIAL: SUBJECT TUMOR TYPE SUBJECT DOSE LEVEL TYPE OF CANCER DIAGNOSED LOCATION # 100-003 0.8 mg/kg Malignant neoplasm of endometrium Uterus 103-001 0.8 mg/kg Solitary fibrous tumor (hemangiopericytoma) Right forehead 100-002 0.8 mg/kg Adenocarcinoma of the rectum Rectum 100-004 1.6 mg/kg Ma
Slide 14: Phase 1a Trial: Safety Primary Endpoint Met
PHASE 1a TRIAL: SAFETY PRIMARY ENDPOINT MET Number Treatment Related Serious Adverse Cohort Dose DLT’s Events (SAE) of Patients 1 0.8mg/kg 3 0 #Subject SAE s (N=16) % Subjects Grade 2 1.6mg/kg 3 0 3.2mg/kg 7 0 Infusion 3 Related 1 6.25% 2 Reaction* 4 4.8mg/kg 3 0 * SAE due to hospitalization observa
Slide 15: Phase 1a Trial: Safety Overview
PHASE 1a TRIAL: SAFETY OVERVIEW ADVERSE EVENT FREQUENCY Adverse Events 62.5% of patients experienced at least ADVERSE EVENT (MAXIMUM CTCAE GRADE) TOTAL (N=16) one treatment-related adverse event Nausea 2 (12.5%) Grade 1’s 2 (12.5%) Hyponatremia 3 (18.8%) SEVERITY OF ADVERSE EVENTS Grade 1’s 2 (12.5%
Slide 16: Phase 1a Trial: Pharmacokinetic Results
PHASE 1a TRIAL: PHARMACOKINETIC RESULTS MEAN CONCENTRATIONS ON C1DI SUPRA-PROPORTIONAL PLASMA EXPOSURE VS. DOSE Pharmacokinetic profile from the analysis of plasma from patients receiving TTX-MC138 demonstrated evidence of drug availability consistent with preclinical data 16
Slide 17: Phase 1a Trial: Efficacy Analysis
PHASE 1a TRIAL: EFFICACY ANALYSIS • 10 of 14 efficacy-evaluable patients (71.4%) achieved SWIMMERS PLOT RESPONSE CATEGORIES stable disease as best overall response by Investigator assessment • Disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1 • Among 13 patients with evaluab
Slide 18: Phase 1a Trial: Thyroid Cancer Case
PHASE 1a TRIAL: THYROID CANCER CASE PATIENT 103-003 THYROGLOBULIN LEVELS Patient 103-003 with metastatic thyroid cancer with lung metastases THYROGLOBULIN LEVELS Associated with increased tumor burden Dropped to 0 after 6 cycles Stable disease radiographically C7 AND C8 DOSE DELAYED Possibly
Slide 19: Phase 2a Trial: TTX-MC138 in Colorectal Cancer Targeting Minimal Residual Disease
PHASE 2a TRIAL: TTX-MC138 IN COLORECTAL CANCER TARGETING MINIMAL RESIDUAL DISEASE OPPORTUNITY: Address unmet medical need by evaluating TTX-MC138 in colorectal patients post adjuvant treatment with “Liquid Biopsies” Detection of Microscopic Disease: curative intent A Diagnostic Shift MECHANISM O
Slide 20: Phase 2a Study: Quantum Leap Healthcare Collaboration
PHASE 2a STUDY: QUANTUM LEAP HEALTHCARE COLLABORATION Accelerate Success - Partnership with the Quantum PLATFORM STUDY PI: Leap Healthcare Collaborative oncology platform DR. PAULA POHLMANN, MD (MD ANDERSON) study PLANNED CLINICAL SITES Rapid Study Initiation - Ready-to-deploy infrastructure and par
Slide 21: Phase 2a Trial Design: Single Arm Open Label
PHASE 2a TRIAL DESIGN: SINGLE ARM OPEN LABEL PATIENT SELECTION ctDNA+ after curative-intent standard therapy TREATMENT N = 45 patients, 4.8 mg/kg, IV, Q28D, 12 cycles CTDNA MONITORING Serial ctDNA analysis every cycle (primary endpoint assessment) RESPONSE ASSESSMENT ctDNA clearance →MRD Negativity,
Slide 22: Seviprotimut-L: Cancer Vaccine
SEVIPROTIMUT-L CANCER VACCINE 22
Slide 23: Seviprotimut-L: Overview and Unmet Needs
SEVIPROTIMUT-L: OVERVIEW AND UNMET NEEDS Novel polyvalent shed antigens vaccine for the adjuvant treatment of Stage IIB and IIC melanoma in patients <60 years of age Keytruda (Merck) & Opdivo (BMS) are checkpoint inhibitors (CPIs) approved for the FDA “Orphan Drug” status adjuvant treatment of mel
Slide 24: Seviprotimut-L: Phase 3 MAVIS Clinical Trial Design & Efficacy Results
SEVIPROTIMUT-L: PHASE 3 MAVIS CLINICAL TRIAL DESIGN & EFFICACY RESULTS STUDY DRUG RECURRENCE-FREE SURVIVAL 40 µg seviprotimut* vs placebo STUDY POPULATION Ages 18 to 80, female and male Stage IIB/IIC, IIIA, and IIIB/IIIC melanoma patients, resected with clear margins Resection within 90 days o
Slide 25: Pre-Clinical Programs
PRE-CLINICAL PROGRAMS 25
Slide 26: UIO 524: Next Generation Oncolytic Virus
UIO 524 NEXT GENERATION ONCOLYTIC VIRUS 26
Slide 27: Next Generation Oncolytic Virus: UIO-524
NEXT GENERATION ONCOLYTIC VIRUS: UIO-524 UIO-524: engineered adenovirus type 5 based oncolytic virus KH-SPARC E1A Rb / CD40L 4-1BBL hTERT Hybrid promoter (SPARC-KR) to drive stromal- E1B-19k tumor specific virus replication Armed with three powerful immunostimulatory genes (CD40L, 4-1BBL and IL-21)
Slide 28: UIO 524: Preclinical POC & Initial Focus for Clinical Development
UIO 524: PRECLINICAL POC & INITIAL FOCUS FOR CLINICAL DEVELOPMENT Human A549 NSCLC (immuno-compromised mice) LOW GRADE MUSCLE INVASIVE BLADDER CANCER (MIBC) Tumor Volume ( mm3 ) 1600 PBS UIO-524 Bladder cancer 9th most common cancer globally (heavily concentrated in men and older adults) 1200 On
Slide 29: TTX Drug Design Engine
TTX DRUG DESIGN ENGINE 29
Slide 30: TTX Tunable Drug Design Engine
TTX TUNABLE DRUG DESIGN ENGINE Customized according to predesigned specifications Nucleic acids Peptides Radionuclides Small Molecules Payload diversity Nanometers Microns Size Non-cleavable pH sensitive Tissue-specific Time-sensitive Smart release linkers Polymers Biomolecules (e.g. glucose) mAbs P
Slide 31: TTX-siPD-L1: RNAi-Based Checkpoint Inhibitor
TTX-siPD-L1 RNAi-BASED CHECKPOINT INHIBITOR 31
Slide 32: Traditional ICI vs TTX-siPD-L1: Mechanistic & Clinical Comparison
TRADITIONAL ICI* VS TTX-siPD-L1: MECHANISTIC & CLINICAL COMPARISON PROPERTIES TRADITIONAL ICI* TTX-siPD-L1 Blocks PD-1/PD-L1 interaction at the siRNA silences PD-L1 gene expression inside tumor Mechanism cell surface cells Tumor-targeted delivery; preferential uptake by tumor Systemic immune activat
Slide 33: TTX-siPD-L1 Generated Robust Response in Mice
TTX-siPD-L1 GENERATED ROBUST RESPONSE IN MICE RESULTS: TTX- siSCR+gem TTX-siPDL1+gem High-dose TTX-siPD-L1 + gemcitabine regressed pancreatic tumors by 90% within the first two weeks of treatment and delayed tumor growth. (Figure A above) Treatment increased survival - 67% of the experimental an
Slide 34: TTX-RIGA: A PRR Agonist
TTX-RIGA A PRR AGONIST 34
Slide 35: TTX-RIGA: RIG-I Signaling
TTX-RIGA: RIG-I SIGNALING Properties Traditional ICI* TTX-RIGA Activate RIG-I broadly, often Tumor-targeted RIG-I activation via nanoparticle Mechanism requiring high doses delivery and template-based activation Limited tumor selectivity; need for Preferential activation in tumors; minimizes systemi
Slide 36: TTX-RIGA: In Vivo Efficacy
TTX-RIGA: IN VIVO EFFICACY C57BL/6 mice were implanted s.c. with B16-F10 cells. Treatment was initiated once tumors were established. Treatment continued until day 6 after tumor implantation. On day 12 after the beginning of treatment, a secondary tumor challenge with the same cell line was performe
Slide 37: TTX Pre-Clinical Programs: Moving Forward
TTX PRE-CLINICAL PROGRAMS: MOVING FORWARD Developing nucleic acid-based therapeutics against cancer depends on successful delivery to tumors and metastases TTX has shown successful delivery to cancerous lesions, including in humans The efficacy of TTX-based nucleic acid therapeutics, e.g. TTX-siPD-L
Slide 38: Finance Overview
FINANCE OVERVIEW 38
Slide 39: Recent Corporate Developments
RECENT CORPORATE DEVELOPMENTS Q4 25 Q1 26 Q2 26 Acquisition of Polynoma Licensing of immuno- $20 million SEPA with oncolytic portfolio from Yorkville Advisors Series A Pref. Unleash Immuno Conv. Notes $25 million investment Oncolytics by CK Life Sciences Common Stock Series B Pref. Series C Pref. 39
Slide 40: Capital Structure
CAPITAL STRUCTURE SHARE PRICE September 14, 2026 $1.65 Shares Outstanding (000) * June 30, 2026 1,012 Market Capitalization ($mm) June 30, 2026 $6.3 Shares Outstanding (000) * Pro Forma 17,149 Market Capitalization ($mm) Pro Forma $28.3 Long-Term Debt June 30, 2026 --- Cash & Equivalents ($mm) Pro F
Slide 41: Investment Thesis
INVESTMENT THESIS 41
Slide 42: Investment Thesis
INVESTMENT THESIS Building an innovative and differentiated oncology company to meaningfully improve the treatment of advanced cancer by developing breakthrough treatment modalities acting on metastatic cancer and enhancing the power of the immune system STRATEGIC FOCUS BALANCED AND PRIORITIZE TTX-M
Slide 43: Near Term Catalysts – Each a Potential Inflection Point
NEAR TERM CATALYSTS – EACH A POTENTIAL INFLECTION POINT Q2 26 Q3 26 Q4 26 1H 27 2H27 TTX-MC138 TTX-MC138 TTX-MC138 TTX-MC138 TTX-MC138 Phase 2a Phase 2a Phase 2a Phase 1a Phase 2a site initiation enrollment preliminary results at completion, update results major preliminary oncology readou
Slide 44: eR AN Ss CASD Ee
eR AN Ss CASD Ee THERAPEUTIC S™